Application of metabolomics to prostate cancer
Copyright © 2011 Elsevier Inc. All rights reserved..
The prostate has long been known to exhibit unique metabolite profiles. In the last decade, advances in nuclear magnetic resonance spectroscopy and mass spectrometry have been applied toward identifying metabolic alterations in prostate cancer that may provide clinically useful biomarkers. As with genomics and proteomics, advances in technology and bioinformatics have led to the application of metabolomic profiling to prostate cancer-the high throughput evaluation of a large complement of metabolites in the prostate and how they are altered by disease perturbations. Recently, high profile publications have drawn attention to the potential of metabolomic analysis to identify biomarkers for early detection or disease progression from readily accessible body fluids as well as tissue specimens from biopsy and surgery. This review will examine applications of metabolomics to prostate cancer and highlight clinical associations and potential challenges.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Urologic oncology - 29(2011), 5 vom: 01. Sept., Seite 572-81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trock, Bruce J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 02.02.2012 Date Revised 17.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.urolonc.2011.08.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM211586781 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM211586781 | ||
| 003 | DE-627 | ||
| 005 | 20240417231945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.urolonc.2011.08.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM211586781 | ||
| 035 | |a (NLM)21930089 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trock, Bruce J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of metabolomics to prostate cancer |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2012 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2011 Elsevier Inc. All rights reserved. | ||
| 520 | |a The prostate has long been known to exhibit unique metabolite profiles. In the last decade, advances in nuclear magnetic resonance spectroscopy and mass spectrometry have been applied toward identifying metabolic alterations in prostate cancer that may provide clinically useful biomarkers. As with genomics and proteomics, advances in technology and bioinformatics have led to the application of metabolomic profiling to prostate cancer-the high throughput evaluation of a large complement of metabolites in the prostate and how they are altered by disease perturbations. Recently, high profile publications have drawn attention to the potential of metabolomic analysis to identify biomarkers for early detection or disease progression from readily accessible body fluids as well as tissue specimens from biopsy and surgery. This review will examine applications of metabolomics to prostate cancer and highlight clinical associations and potential challenges | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 773 | 0 | 8 | |i Enthalten in |t Urologic oncology |d 1995 |g 29(2011), 5 vom: 01. Sept., Seite 572-81 |w (DE-627)NLM097435058 |x 1873-2496 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2011 |g number:5 |g day:01 |g month:09 |g pages:572-81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.urolonc.2011.08.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2011 |e 5 |b 01 |c 09 |h 572-81 | ||